Clinical Trials Browser

Active not recruiting × Interventional × IRX 2 × Clear all

NCT04373031 2025-12-02

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase 2 Active not recruiting

12 enrolled 11 charts

Breast Neoplasms

NCT03655002 2025-06-17

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular